All In Biotech

Drug Trial Radar · NCT03578900

Quality of Life and Sjögren Syndrome

Quality of Life in a Portuguese Population With Primary Sjögren Syndrome

Last checked: Nov 20, 2026Latest source record: Jul 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 289 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

289

Actual

Start

Jan 1, 2013

Primary completion

Dec 31, 2014

Study completion Dec 31, 2016

Sponsor

Lead sponsor
Grupo de Investigação em Bioquímica e Biologia OralAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
University of Lisbon; Portuguese Institute of Rheumatology; Dentaid SL
First posted
Jul 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Crossover
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aims of this study are: To compare salivary pH changes and stimulation efficacy of two different Gustatory Stimulants of Salivation (GSSS) in patients with Primary Sjögren Syndrome (PSS); To evaluate Primary Sjögren syndrome (PSS) impact and gustatory stimulants of salivary secretion (GSSS) on oral health related quality of life measured by a Portuguese version of Oral Health Impact Profile-14 (OHIP-14) and specific Xerostomia assessment questionnaires. The Products to be used are the Xeros® Dentaid system and a citric based mouthwash.

Conditions

  • Xerostomia
  • Hyposalivation
  • Quality of Life
  • Sjogren's Syndrome

Interventions

  • XerosDrug

  • Citric Acid based MouthwashDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time of GSSS induced pH drop below 4.5Time frame: 20 minutes
  2. Overall and sub domains scores for each questionnaireTime frame: 15 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.